（来源：ETF炼金师） 近期，港股市场的创新药板块引发了投资者的广泛关注。特别是在恒生科技（互联网）ETF的前景下， 投资者对港股创新药的前景充满期待。在分析这一领域的动态时，需要明确投资的时间框架，是中长线 投资还是短线交易。 在中长线投资的视角下，港股的医药企业的中期财报和政策面表态显得尤为重要。近期，恒瑞医药的中 报显示出积极的现金流状况，尽管其股价在港股市场表现平平，但相较A股已存在10%的溢价。此外， 药明生物和药明合联等CXO企业的中报也亮眼，受到了外资投行的积极评价，这表明外资对当前市场 的价值认可与信心。 然而，并非所有企业的表现都如预期，率先披露的再鼎医药虽然减亏，但未能达到市场预期，导致其股 价在短期内受到打压。市场普遍处于中报观望期，龙头企业如信达、百济、石药和康方等将在未来几天 集中发布财报，投资者需保持警惕。 针对短线交易的策略，外资的态度和市场资金的共识是关键。港股医药板块的定价权主要掌握在外资手 中，外部环境的稳定与否将直接影响投资者的操作策略。如果外资对创新药板块失去兴趣，可能会带来 整体的抛压，但目前并没有明显迹象表明外资会撤离。 在技术面分析中，近期资金的流入情况显示出稳健 ...

Core Viewpoint - The company reported better-than-expected performance for 1H25, driven by smooth project progress, commercialization ramp-up, and improved operational efficiency [1] Financial Performance - Revenue for 1H25 reached 9.95 billion yuan, a year-on-year increase of 16.1%, with continuing operations revenue up by 20.2% [1] - Gross margin stood at 42.7%, an increase of 3.6 percentage points year-on-year [1] - Adjusted EBITDA was 4.31 billion yuan, up 20.6% year-on-year, corresponding to a profit margin of 43.3% [1] - Adjusted net profit reached 2.84 billion yuan, a year-on-year increase of 11.6%, with a corresponding profit margin of 28.5% [1] - The company raised its revenue growth forecast for 2025 to 14%-16% and indicated steady profit level improvements and significant free cash flow growth [1] Business Development Trends - The CRDMO business model is fully operational, with over 50 molecular projects empowered as of 1H25, and potential milestone payments reaching 9 billion USD [2] - Revenue from preclinical stage projects was 4.15 billion yuan, a year-on-year increase of 35.2%, driven by research services and preclinical development project revenue conversion [2] - Revenue from Phase III clinical and commercialization stages was 4.29 billion yuan, up 24.9% year-on-year, benefiting from the advancement of early projects and ongoing commercialization [2] - The company has 67 Phase III clinical projects and 24 commercialization projects as of 1H25, with 25 PPQ projects scheduled for 2025 [2] - A total of 86 new projects were signed in 1H25, with over 70% being bispecific, multi-specific, and ADCs, showcasing the company's complex molecular technology capabilities [2] - The company secured 9 new molecules in 1H25, including 2 Phase III projects, primarily from the U.S. [2] - The backlog of uncompleted orders reached 20.3 billion USD, with approximately 4.2 billion USD in orders not completed within three years [2] Global Capacity Expansion - Capital expenditure for 1H25 was approximately 1.9 billion yuan, with an expected total of 5.3 billion yuan for the year [3] - In Singapore, the modular biopharmaceutical (DP) production facility has commenced construction, while the modular raw material (DS) production facility is in the design phase [3] - In Ireland, MFG6.2 has completed its first engineering batch and PPQ production, while MFG7 has completed its second 12kL scale PPQ production [3] - In the U.S., construction of MFG11 is ongoing, providing end-to-end R-D-M services [3] - In China, the 15kL raw material production line in Hangzhou has completed its first commercial PPQ production, and the Chengdu microbial commercialization base has officially started construction [3] Profit Forecast and Valuation - Due to smooth project progress and improved operational efficiency, the company raised its net profit forecast for 2025/2026 by 5.5%/1.6% to 4.21/4.71 billion yuan [3] - Adjusted profit forecasts for 2025/2026 were increased by 2.5%/4.1% to 5.11/5.58 billion yuan [3] - The company maintains an outperform rating, with the current stock price corresponding to adjusted P/E ratios of 21.7x/19.6x for 2025/2026 [3] - The target price was raised by 10.8% to 36 HKD, corresponding to adjusted P/E ratios of 26.3x/23.7x for 2025/2026, indicating a potential upside of 20.9% from the current stock price [3]

Investment Rating - The report maintains a "Buy" rating for WuXi Biologics (2269.HK) [4] Core Views - WuXi Biologics continues to show robust growth in its mid-year performance for 2025, with revenue reaching 9.95 billion RMB, a year-on-year increase of 16.1%, and an adjusted net profit of 2.84 billion RMB, up 11.6% year-on-year [1] - The company is positioned as a global leader in the biopharmaceutical CRDMO sector, with a strong order backlog and increasing capacity utilization expected to drive steady growth in the coming years [4] Summary by Sections Financial Performance - For the first half of 2025, WuXi Biologics reported total revenue of 9.95 billion RMB, with a gross margin of 42.7%, reflecting a 3.6 percentage point increase year-on-year [1] - Adjusted net profit for the same period was 2.84 billion RMB, representing an 11.6% increase compared to the previous year [1] Business Segmentation - Revenue by project phase shows a diverse growth pattern: - Preclinical projects generated 4.15 billion RMB, up 35.2% year-on-year - Early clinical projects saw a decline to 1.33 billion RMB, down 29.7% year-on-year - Phase III and commercial projects achieved 4.29 billion RMB, an increase of 24.9% year-on-year [1] Regional Performance - Revenue by region indicates strong performance in North America, with a 20.1% year-on-year increase, accounting for 60.5% of total revenue. Europe grew by 5.7%, while China experienced a decline of 8.5%. Other regions, including Singapore, Japan, and South Korea, saw a significant increase of 136.1% [2] Order Backlog and Project Pipeline - The total number of projects reached 864, with a year-on-year increase of 16.4%. The company signed 86 new projects in the first half of 2025, with over 50% coming from the U.S. [3] - The total backlog of uncompleted orders reached 20.3 billion USD, with potential milestone payments at a historical high of 9.0 billion USD, indicating strong revenue growth expectations [3] Future Outlook - The company is expected to achieve net profits of 4.37 billion RMB, 4.81 billion RMB, and 5.27 billion RMB for the years 2025, 2026, and 2027, respectively, with growth rates of 30.2%, 10.1%, and 9.6% [4] - The projected P/E ratios for the next three years are 27, 24, and 22, indicating a favorable valuation outlook [4]

Core Viewpoint - The report from Credit Lyonnais indicates that potential royalties and milestone payments, in addition to development and production, are expected to be key drivers for WuXi Biologics' long-term growth, leading to an upward revision of revenue and net profit forecasts for 2025 to 2027 [1] Group 1 - WuXi Biologics' sales increased by 16% year-on-year in the first half of the year, with adjusted net profit rising by 12%, aligning with market expectations [1] - The management has raised the full-year revenue growth guidance from 12%-15% to 14%-16%, anticipating accelerated growth in unfulfilled orders to support the company's long-term growth [1] Group 2 - Revenue forecasts for 2025 to 2027 have been adjusted upward by 2% to 9%, while net profit forecasts for 2026 to 2027 have been increased by 6% to 12% to reflect strong mid-term performance and robust order growth [1] - The target price for WuXi Biologics has been raised from HKD 28.8 to HKD 34.8, maintaining an "outperform" rating [1]

智通财经APP获悉，里昂发布研报称，除开发与生产外，潜在特许权使用费及里程碑费用料将成为药明 生物(02269)长期增长关键驱动力，相应将2025至2027年收入预测上调2%至9%，并将2026年至2027年净 利润预测上调6%至12%，以反映中期业绩表现强劲及订单增长稳健，目标价从28.8港元上调至34.8港 元，维持"跑赢大市"评级。 里昂表示，药明生物上半年销售额同比增长16%，经调整净利润同比增长12%，符合市场预期。管理层 将全年收入增长指引从12%至15%，上调至14%至16%，预期未完成订单加速增长，将支持公司的长期 增长。 ...

大和发布研报称，药明生物(02269)2025年上半年业绩符合预期，收入、毛利率及积压订单均实现强劲 增长，研发-开发-生产(RDM)各环节在2025年下半年能见度高，毛利率预计持续改善，该行重申"买 入"评级。针对2025至2027年预测，将毛利率预测上调1.5至1.6个百分点，并将销售及管理费用预测下调 7%，以反映2025年上半年最新趋势。因此，将2025至2027年每股盈利预测上调3%至10%，目标价由30 港元上调至35.5港元。 ...

Core Viewpoint - Daiwa's report indicates that WuXi Biologics (02269) achieved expected performance in the first half of 2025, with strong growth in revenue, gross margin, and backlog orders [1] Group 1: Financial Performance - Revenue, gross margin, and backlog orders all showed robust growth in the first half of 2025 [1] - The gross margin forecast for 2025 to 2027 has been raised by 1.5 to 1.6 percentage points [1] Group 2: Cost Management - Sales and management expense forecasts have been reduced by 7% to reflect the latest trends observed in the first half of 2025 [1] Group 3: Earnings Forecast - Earnings per share forecasts for 2025 to 2027 have been increased by 3% to 10% [1] - The target price has been raised from HKD 30 to HKD 35.5 [1]

Core Viewpoint - The Hong Kong stock market's AI healthcare sector is experiencing significant activity, with notable gains in various stocks and ETFs, particularly driven by the performance of Ping An Good Doctor [1] Group 1: Market Activity - The Hong Kong Medical ETF (159366) saw an intraday increase of over 2%, with constituent stocks like Ping An Good Doctor (01833) rising over 15% and Kingsoft Biotech (01548) increasing by 6.24% [1] - The trading volume for the Hong Kong Medical ETF reached 235 million yuan, with a turnover rate of 73.21% [1] - Over the past week, the average daily trading volume for the Hong Kong Medical ETF was 381 million yuan [1] Group 2: Company Performance - Ping An Good Doctor reported a total revenue of 2.5 billion yuan for the first half of 2025, marking a year-on-year growth of 19.5%, and a net profit of 134 million yuan, a significant increase of 136.8% [1] - The company's F-end and B-end business segments saw a revenue increase of 30.2%, with the overall number of paying users rising by 35.1% [1] Group 3: AI Investment and Innovation - Ping An Good Doctor is heavily investing in AI, with successful product developments such as "Ping An Xinyi" and "An Director," which enhance the company's service offerings and operational efficiency [2] - The company has established a top-tier medical network to support its AI products, which assist in patient consultations and follow-ups [2] Group 4: Industry Trends - JD Health reported a revenue of approximately 35.29 billion yuan for the first half of 2025, reflecting a year-on-year increase of 24.5%, with AI playing a crucial role in enhancing healthcare services [3] - The Chinese government has reinforced its support for AI in healthcare, which is expected to accelerate the commercialization of AI applications in the sector [3] Group 5: Index Composition - As of July 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index accounted for 58.42% of the index, including major players like WuXi Biologics (02269) and JD Health (06618) [4]

Core Viewpoint - Daiwa's report indicates that WuXi Biologics' performance in the first half of the year met expectations, with strong growth in revenue, gross margin, and backlog orders [1] Group 1: Financial Performance - Revenue, gross margin, and backlog orders all showed robust growth [1] - Gross margin forecasts for 2025 to 2027 have been raised by 1.5 to 1.6 percentage points [1] - Earnings per share forecast has been increased by 3% to 10% [1] Group 2: Cost Management - Sales and management expense forecasts have been reduced by 7% to reflect the latest trends in the first half of 2025 [1] Group 3: Target Price and Rating - The target price has been raised from HKD 30 to HKD 35.5 [1] - The "Buy" rating has been reaffirmed [1]

Global Market Overview - The Hang Seng Index closed at 25,166, down 0.41% for the day but up 25.45% year-to-date [1] - The Shanghai Composite Index rose by 1.88% to 3,766, with a year-to-date increase of 12.37% [1] - The US markets showed mixed results, with the Dow Jones down 0.05% and the S&P 500 down 0.60%, while the Nasdaq fell by 1.42% [1] Hong Kong Stock Performance - The Hang Seng Financial Index decreased by 0.42% to 44,940, with a year-to-date increase of 27.90% [2] - The Hang Seng Property Index fell by 1.15% to 18,493, but is still up 24.01% year-to-date [2] - Southbound capital saw a net sell-off of HKD 14.68 billion, with major sell-offs in ETFs like the Tracker Fund and Hang Seng China Enterprises [3] Company Insights Guoquan (锅圈) - Guoquan is the leading brand in China's home dining solutions, achieving retail sales of RMB 11.1 billion in 2022, with a market share of 3% [5] - The company operates over 10,150 stores and is expected to generate approximately RMB 6.5 billion in sales for the fiscal year 2024 [5] - Guoquan's C2F model offers advantages to consumers and suppliers, with a diverse product range and a focus on quality and safety [5][6] Baidu - Baidu's Q2 2025 performance exceeded market expectations, with core business revenue of RMB 26.3 billion, a 2% year-on-year decline but 1.6% above consensus [8] - The company is focusing on growth in its autonomous driving and cloud services, which are expected to drive long-term revenue and profit growth [8] Boss Zhipin - Boss Zhipin reported a 10% year-on-year revenue increase to RMB 2.1 billion in Q2 2025, with non-GAAP net profit rising by 31% to RMB 941 million [8] - The company anticipates a revenue growth of 11.4%-13.0% in Q3 2025, driven by an improving supply-demand environment [8] Keren Biotechnology - Keren Biotechnology expects to release significant data at the 2025 ESMO conference, with SKB264 projected to generate sales of RMB 800 million to RMB 1 billion [9][10] - The company is actively advancing multiple Phase III clinical trials for SKB264, targeting various cancer indications [11] WuXi Biologics - WuXi Biologics reported a 16.1% year-on-year revenue increase to RMB 9.953 billion in H1 2025, driven by strong demand in both R&D and manufacturing sectors [13] - The company has raised its full-year revenue growth guidance to 14-16%, reflecting robust client demand [13][14] ZTO Express - ZTO Express has adjusted its annual package volume growth forecast to 14-18%, down from 20-24%, in response to government policies [16] - Despite a 26% year-on-year profit decline in Q2 2025, the company anticipates that single-package prices may exceed expectations, serving as a catalyst for stock price growth [16] China General Nuclear Power Corporation - China General Nuclear Power Corporation issued a profit warning for H1 2025, expecting a net loss between HKD 40 million and HKD 90 million, aligning with previous forecasts [17] - The company has signed an underwriting agreement with its parent company, which is expected to significantly increase contract prices starting in 2026, driving future profit growth [17]